TABLE 2.

Efficacy and potency of benralizumab and mepolizumab after overnight incubation on the airway hyperresponsiveness to different concentrations of histamine (EC_50–90) in passively sensitized bronchi

Contractile tone to histamine at	Benralizumab			Mepolizumab
	EC50	EC70	EC90	EC50	EC70	EC90
Benralizumab or mepolizumab Emax (mg·100 mg−1 bronchial tissue)	−116.05 ± 13.60	−111.90 ± 13.28	−134.14 ± 14.93	−101.06 ± 29.91	−104.33 ± 29.93	−108.29 ± 32.16
Benralizumab or mepolizumab pIC50	8.24 ± 0.16**	8.13 ± 0.12*	7.94 ± 0.19*	7.41 ± 0.18	7.44 ± 0.17	7.28 ± 0.19

Note: The pharmacological analysis was performed by assessing E_max as the difference in airway contractility between C+ and C− tissues. Data represent the mean ± SEM of n = 5 bronchial tissue from different subjects.

Abbreviations: C+, positive control, passively sensitized bronchi; C−, negative control, non‐sensitized bronchi; EC_n, concentration inducing n% E_max; E_max, maximal effect; IC₅₀, concentration inducing 50% inhibition airway hyperresponsiveness to histamine in passively sensitized bronchi; pIC₅₀, −logIC₅₀.

^* P < 0.05 versus mepolizumab (statistical analysis assessed by the Student's t‐test).